Released Nov 14, 2019, after the close
10-Q filed Nov 14, 2019, 45 days after period end · 0001390478-19-000056
Q3 2019 · 10-Q
Revenue—
Net Income-$4.20M-$4.20M N/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$2.68-$2.68 N/M vs Q3 2018N/M vs Q2 2019
Operating Cash Flowderived-$3,820,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2019 | Q3 2018 | Q3 2017 | Q3 2016 |
|---|---|---|---|---|
| Net Income | -$4.20M | -$290.00K | -$4.46M | -$6.93M |
| EPS Diluted | -$2.68 | -$26.75 | -$2.27 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR